BRIEF-Nicox unveils positive Phase III results for eye drug

Thu Sep 25, 2014 2:18am EDT
 
Email This Article |
Share This Article
  • Facebook
  • LinkedIn
  • Twitter
| Print This Article
[-] Text [+]

Sept 25 (Reuters) - Nicox :

* Nicox and Valeant Pharmaceuticals announce positive top-line results from pivotal phase 3 studies conducted with Vesneo (latanoprostene bunod)

* Says studies met their primary endpoint and showed positive results on a number of secondary endpoints

* Says product has peak sales potential of around $500 million+ in U.S. and over $1 billion globally

* Says Bausch + Lomb expects to submit a new drug application to the FDA for approval of Vesneo in mid-2015 Source text for Eikon: Further company coverage: